BT Group plc (LON:BT.A)
185.90
+1.40 (0.76%)
Oct 20, 2025, 6:33 PM BST
BT Group Employees
BT Group had 85,300 employees as of March 31, 2025. The number of employees decreased by 6,400 or -6.98% compared to the previous year.
Employees
85,300
Change (1Y)
-6,400
Growth (1Y)
-6.98%
Revenue / Employee
238.66K GBP
Profits / Employee
12.36K GBP
Market Cap
18.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 85,300 | -6,400 | -6.98% |
Mar 31, 2024 | 91,700 | -5,400 | -5.56% |
Mar 31, 2023 | 97,100 | -1,300 | -1.32% |
Mar 31, 2022 | 98,400 | -1,300 | -1.30% |
Mar 31, 2021 | 99,700 | -5,600 | -5.32% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
WPP plc | 108,044 |
Vodafone Group | 88,780 |
Pearson | 17,116 |
Informa | 13,214 |
Canal+ | 9,087 |
ITV plc | 6,133 |
Airtel Africa | 4,253 |
Zegona Communications | 2,400 |
BT Group News
- 14 hours ago - Internet outages at HMRC, Zoom and Snapchat reported after AWS disruption - Evening Standard
- 16 hours ago - Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors - Accesswire
- 17 hours ago - Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors - GlobeNewsWire
- 2 days ago - Heathrow puts Jansen on runway as next chairman - Sky News
- 4 days ago - More 'punitive' tax hikes would wreck economy: BT and Whitbread in stark warning ahead of Budget - This is Money
- 4 days ago - Man Arrested For Threatening Karnataka Minister Priyank Kharge Over RSS Ban - NDTV
- 4 days ago - Proposed changes to business rates ‘risk slowdown’ in investment, warns BT - Evening Standard
- 7 days ago - Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025 - Accesswire